Investment Thesis
Pliant Therapeutics exhibits a reasonably healthy balance sheet with strong liquidity and zero debt, but faces critical execution risk as a pre-revenue pharmaceutical company burning approximately $19.2M annually with only ~1.2 years of cash runway. Success depends entirely on clinical development progress and future financing or revenue generation.
Strengths
- Strong balance sheet with $165.2M stockholders' equity and minimal liabilities of $37.4M
- Excellent liquidity position with 16.89x current ratio and $22.2M cash reserves; zero long-term debt
- Improving EPS metrics year-over-year (+30%) suggests better operational efficiency or reduced share dilution
Risks
- Limited cash runway of approximately 1.2 years at current burn rate of $19.2M annually
- Zero revenue indicates pre-commercialization stage with no validated business model or clinical success achieved
- Negative operating cash flow will likely require significant future capital raises, creating substantial shareholder dilution risk
Key Metrics to Watch
- Quarterly cash burn rate and remaining months of cash runway; trajectory of operating cash flow
- Clinical trial progress and regulatory milestones for pharmaceutical pipeline programs
- Capital structure changes including equity or debt financing announcements
Financial Metrics
Revenue
0.0
Net Income
-20.0M
EPS (Diluted)
$-0.32
Free Cash Flow
-19.2M
Total Assets
202.6M
Cash
22.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-12.1%
ROA
-9.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
16.89x
Quick Ratio
16.89x
Debt/Equity
0.00x
Debt/Assets
18.5%
Interest Coverage
-48.93x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:58:22.828846 |
Data as of: 2026-03-31 |
Powered by Claude AI